Equities

MedPlus Health Services Ltd

MEDPLUS:NSI

MedPlus Health Services Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (INR)704.25
  • Today's Change7.35 / 1.05%
  • Shares traded970.43k
  • 1 Year change-13.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 10:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 6 analysts offering 12 month price targets for MedPlus Health Services Ltd have a median target of 906.83, with a high estimate of 1,100.00 and a low estimate of 820.00. The median estimate represents a 28.63% increase from the last price of 705.00.
High56.0%1,100.00
Med28.6%906.83
Low16.3%820.00

Earnings history & estimates in INR

While analysts are not providing 2nd quarter earnings estimates for MedPlus Health Services Ltd, they are predicting full year 2025 earnings of 142.70 per share. On Nov 12, 2024, MedPlus Health Services Ltd reported 2nd quarter 2025 losses of -- per share.
The next earnings announcement is expected on May 28, 2025.
Average growth rate+22.45%
MedPlus Health Services Ltd reported annual 2024 earnings of 5.45 per share on May 28, 2024.
Average growth rate-10.18%
More ▼

Revenue history & estimates in INR

MedPlus Health Services Ltd had 2nd quarter 2025 revenues of 15.76bn. This missed the 15.92bn estimate of the one analyst following the company. This was 22.73% above the prior year's 2nd quarter results.
Average growth rate+2.87%
MedPlus Health Services Ltd had revenues for the full year 2024 of 56.25bn. This was 23.42% above the prior year's results.
Average growth rate+22.01%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.